State of the Art Review on the Treatment of Psoriatic Disease

Eleftherios Pelechas¹, Evripidis Kaltsonoudis¹, Michalis P. Migkos¹, Nikolaos Koletsos¹, Panagiota G. Karagianni², Alexandros A. Drosos¹, Paraskevi V. Voulgari¹

¹Department of Rheumatology, Medical School, University of Ioannina, Ioannina, Greece
²Department of Microbiology, Medical School, University of Ioannina, Ioannina, Greece

Corresponding Author: Eleftherios Pelechas, PhD, MSc, MAc, Department of Rheumatology, Medical School, University of Ioannina, Ioannina 45100, Greece; Tel.: +30 6979 868 855, E-mail: pelechas@doctors.org.uk

INTRODUCTION

Psoriasis is a chronic inflammatory disease that is characterised by skin lesions which in some cases are accompanied by systemic manifestations. Due to its high heterogeneity, the World Health Organisation (WHO) has classified psoriasis as a serious disease.¹ It affects 2-3% of the population and presents significant effects on the physical and mental health of the patients.²,³ Psoriatic lesions result from an increased proliferation and disturbed differentiation of the keratinocytes.⁴ In the majority of cases, skin lesions precede joint manifestations as well as other organ infestations (bowel, eyes). Given the aforementioned various clinical manifestations, the term psoriatic disease probably reflects in a better manner the whole clinical picture of those affected.⁵ In addition, psoriatic disease may develop a variety of well-known associated comorbidities including cardiovascular disease, obesity and metabolic syndrome, diabetes, osteoporosis, malignancy, fatty liver disease, depression, and anxiety.⁶ Various immune-mediated cellular pathways such as that of TNF-α, IL-23, and IL-17 are involved in the pathophysiology of psoriasis and psoriatic arthritis, and their understanding has led to remarkably better control of it.⁵,⁷ Nowadays, there are various treatment options that are already approved by the regulatory bodies and rely on blocking those cytokines with good to excellent results so far. The main aim of the so-called targeted treatments with biologics is the long-term modulation of the psoriatic disease, with immediate but also long-term results of the signs and symptoms of the disease including the radiological progression. Finally, there is a growing body of evidence that not only the psoriatic disease in sine gets improved, but also several comorbidities can
Various clinical and genetic phenotypes are involved in psoriasis making the same disease to respond in a different manner when it comes to therapeutic regimens. Moreover, apart from the skin and joints, the targeted therapeutic options are affected by the presence of the comorbidities. On the other hand, it has been shown by different studies that some biomarkers can be used in order to assess the response of the disease but due to different settings they can't be reliably used at the moment unanimously on an everyday clinical practice.\(^9\) Thus, the heterogeneity of the disease on one hand and the lack of specific biomarkers on the other hand, lead to a therapeutic ineffectiveness in some instances. One example is this of apremilast, a phosphodiesterase-4 inhibitor, that has significant data on effectiveness and safety for skin psoriasis, but modest results on the polyarticular psoriatic arthritis, and almost no effect on the axial phenotype of the disease.\(^10\) This is the reason that the European League Against Rheumatism (EULAR) on the last update for the treatment of psoriatic arthritis does not include it as a potent agent as the newer biologic disease-modifying anti-rheumatic drugs (bDMARDs) or the Janus Kinase (JAK) inhibitors.\(^11\)

**CURRENT UNMET NEEDS**

Despite the significant progress in the treatment of psoriatic disease (Table 1), there is a proportion of patients that do not respond or develop side effects on the available targeted treatments.\(^12\) In some clinical trials with bDMARDs, it has been reported that up to 40% of the patients are not responding. In fact, in obese patients the percentage is even higher, reaching approximately 50%, when one must have in mind that the psoriatic disease can be affected by emotional instability and stress which is more prevalent in obese people.\(^13\) On the other hand, obesity is not used as a prognostic factor for treatment response, and this is something that could be used in the future.\(^14\) Moreover, the phenomenon of the secondary failure in psoriasis treatment is well-established, and it seems that approximately 30% of the patients will discontinue a tumour necrosis factor \(\alpha\) (TNF\(\alpha\)) agent within one year of treatment. This is even more prevalent in obese women with various comorbidities.\(^15\)

Real-world data showed that a poor treatment response has a negative impact on the patients' quality of life regardless of age, sex, smoking habits, body mass index (BMI), and disease duration. In these cases of primary treatment failure, a timely change of treatment to another biologic agent is preferred. On the other hand, despite the low treatment persistence on patients that changed from a TNF\(\alpha\) inhibitor to another, this treatment strategy is currently applauded because a percentage of the patients will finally respond.\(^16\) In addition, despite the newer biologic agents with different mode of action, there is not a significant improvement either, with a similar percentage of patients failing to respond as seen in naïve patients.\(^16,17\) Thus, an oxymoron is achieved with the treatment strategies. We have better medicines but the patients are undertreated achieving a low disease activity only in 17% of those on conventional synthetic (cs)DMARDs and 57% in those on bDMARDs.\(^18\) Under these circumstances, a personalised treatment regimen should be applied to these patients using all the available guidelines and treatment algorithms from the EULAR, the American College of Rheumatology (ACR), and the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA).\(^11,19-20\) Ideally, treatment strategies should be based on the phenotypic differences of the T-helper cells. This kind of strategies showed significantly higher effectiveness in comparison with the typical treatments with bDMARDs,underlining the importance of precise medicine or personalised medicine strategies.\(^21\)

Since then, and after discussing with the patients, we should focus on patients' characteristics such as extra-articular manifestations and comorbidities, and choose the right treatment for them.

**PATHOPHYSIOLOGY OF PSORIATIC DISEASE**

The discovery of novel drivers of inflammation in psoriatic arthritis (PsA) have led to the identification of IL-17 which is produced by several cells, in addition to CD4+ T-helper (Th17) cells, and which raises the potential for novel pathogenic pathways in psoriasis and the PsA. Traditionally, CD4 and CD8 lymphocytes display pathogenic phenotypes at the sites of disease. The responses of these cells to non-conventional immune stimuli may explain clinical features of these diseases and potential therapeutic mechanisms of therapies such as the JAK inhibitors.\(^22\) Also, from 2003 to 2016 there was a therapeutic "dominance" of the TNF\(\alpha\) inhibitors. But the discovery of the IL-23/IL-17 pathway in 2005, set new therapeutic targets for molecules and signalling pathways. These proved crucial in the pathophysiology of not only axial spondyloarthritis, but also psoriasis and PsA (psoriatic disease). However, the microenvironment
of tissue-specific inflammation in each disease differs. IL-17 secretion in the skin appears to be mediated by local IL-23 production, whereas IL-17 production at the entheses (both on axial and peripheral joints) may be independent of IL-23. IL-23 is involved in the Th17 cell differentiation, mediating the conversion of non-pathogenic Th17 cells into pathogenic that can then migrate to local tissues. Traditionally, it has been thought that a major source of IL-17 is T-cells and that IL-17 production is under the control of IL-23. This seems to have changed today as a number of other cells contribute to its production. In any case, the IL-23 and IL-17 cytokines have an important role both in the pathogenesis and as a therapeutic target and this has been shown in animal models and in humans as far as it concerns some chronic inflammatory diseases.

### THE TRANSITION OF PSORIASIS TO PSORIATIC ARTHRITIS

It is well documented that, in the vast majority of cases, psoriasis may appear years before joint involvement and a review of twenty epidemiologic studies found that the reported proportion of psoriatic arthritis among psoriasis patients ranges from 7-26%. During this time, various environmental, microbial and genetic factors contribute to the transition of inflammation from the skin to the joints. Some of the known risk factors are severe psoriasis, onychopсорiasis, obesity, smoking, and alcohol. Since no diagnostic criteria or specific tests are available, diagnosis is usually based on the identification of inflammatory musculoskeletal features in the joints, and the presence of psoriasis of the skin and/or nails (onychopсорiasis). Based on current therapeutic practice, the initiation of medication is done in the established disease (CASPAR criteria), i.e. where there is clinical symptomatology and/or imaging evidence. But, having in mind that there is a better understanding of the disease in a molecular basis we need to explore more in the direction of developing new methods in order to start treatment at a preclinical stage. This may significantly improve both short-term and long-term outcomes.

---

#### Table 1. Overview of biologics and small molecules for the treatment of psoriatic arthritis.

<table>
<thead>
<tr>
<th>Drug</th>
<th>Structure</th>
<th>Mechanism of action</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>Adalimumab</td>
<td>Fully human IgG1 monoclonal antibody</td>
<td>TNFα inhibitor</td>
<td>40mg subcutaneous every other week</td>
</tr>
<tr>
<td>Certolizumab</td>
<td>Pegylated humanised antigen-binding fragment (Fab) of an anti-TNF monoclonal antibody</td>
<td>TNFα inhibitor</td>
<td>200mg subcutaneous every other week or 400mg every 4 weeks, post induction</td>
</tr>
<tr>
<td>Etanercept</td>
<td>Recombinant human fusion protein</td>
<td>Soluble TNF receptor (TNF inhibitor)</td>
<td>50mg subcutaneous weekly</td>
</tr>
<tr>
<td>Golimumab</td>
<td>Fully human IgG1 monoclonal antibody</td>
<td>TNF inhibitor</td>
<td>50mg subcutaneous monthly</td>
</tr>
<tr>
<td>Infliximab</td>
<td>Chimeric IgG1 monoclonal antibody</td>
<td>TNF inhibitor</td>
<td>5mg/Kg intravenous every 8 weeks, post induction</td>
</tr>
<tr>
<td>Secukinumab</td>
<td>Human IgG1 monoclonal antibody</td>
<td>IL-17A inhibitor</td>
<td>150mg subcutaneous monthly, post induction</td>
</tr>
<tr>
<td>Ixekizumab</td>
<td>Humanised IgG4 monoclonal antibody</td>
<td>IL-17A inhibitor</td>
<td>80mg subcutaneous every 4 weeks, post induction</td>
</tr>
<tr>
<td>Ustekinumab</td>
<td>Fully human IgG1 monoclonal antibody</td>
<td>p40 subunit of IL-12/IL-23</td>
<td>45mg subcutaneous every 12 weeks, post induction. 90mg used for BW&gt;100Kg.</td>
</tr>
<tr>
<td>Apremilast</td>
<td>Targeted synthetic agent</td>
<td>PDE4 inhibitor</td>
<td>30mg po BID, post titration</td>
</tr>
<tr>
<td>Tofacitinib</td>
<td>Targeted synthetic agent</td>
<td>JAK1/JAK3 inhibitor (predominantly)</td>
<td>5mg po BID</td>
</tr>
<tr>
<td>Upadacitinib</td>
<td>Targeted synthetic agent</td>
<td>JAK1 selective inhibitor</td>
<td>15mg po daily</td>
</tr>
</tbody>
</table>

TNF: tumour necrosis factor; IL: interleukin; PDE: phosphodiesterase; JAK: Janus Kinase; BW: body weight; BID: twice a day.
term outcomes, by improving musculoskeletal and skin manifestations, as well as reducing the radiographic damage.

NEW BIOLOGIC TREATMENTS

Newer available biologic therapies (Table 2) have been studied and their arrival may, and is expected, to fill an important therapeutic gap.

JAK inhibitors

The Janus Kinase (JAK) inhibitors are small molecules of great importance since blockade of the JAK kinase receptor downregulates the production of cytokines that are important in the pathogenesis of PsA. Tofacitinib, an orally administered inhibitor (mainly JAK1 and JAK3), has shown its efficacy in multiple levels of disease activity, and after two pivotal phase 3 trials, it has been approved in combination with methotrexate (MTX) for the treatment of PsA.\(^{32}\) Upadacitinib is a more selective JAK inhibitor (JAK1), which through two pivotal phase 3 trials, (SELECT-PsA 1 and SELECT-PsA 2) has demonstrated efficacy in multiple levels of disease activity.\(^{33,34}\) The extension of these studies showed sustained efficacy at 56 weeks. The safety profile of upadacitinib was consistent with previously reported results in all indications, with no new safety signals. These two studies approved the drug at a dosage scheme of 15mg per day for patients with PsA refractory to treatment with csDMARDs. Filgotinib (200mg per day), also a selective oral JAK 1 inhibitor, was evaluated in a phase 2 study (EQUATOR).\(^{35}\) It included 131 patients with failure to control the disease on csDMARDs and was compared with a placebo group. Response was seen rapidly from week 1, while adverse events were similar between the two groups. There have been concerns about testicular toxicity, which is being studied in the MANTA-RAy study, the results of which are eagerly awaited.

Finally, review and meta-analysis of the results of JAK inhibitors (as far as it concerns their safety and efficacy) with five randomised controlled trials (RCTs) of 3293 PsA patients treated with different JAK inhibitors of placebo (2 phase III studies for tofacitinib, 1 phase II study for filgotinib and 2 phase III studies for upadacitinib), demonstrated a statistically significant benefit of JAK inhibitors over placebo in terms of efficacy without emerging any new safety signals.

TYK inhibitors

TYK2 inhibitors differ from JAK inhibitors in binding to the active site in the kinase domain. It is an intracellular kinase that mediates IL-23, IL-12, and interferon α/β. Data from a phase II study for deucravacitinib, showed that it was effective for the treatment of active PsA.\(^{36}\) Both 6mg and 12mg dosage schemes, showed a significant ACR20 response at week 16 compared to placebo (52.9%, 62.7%, and 31.8% respectively). It was also effective in several secondary endpoints, including ACR50/70 and enthesis, with no safety issues related to venous thromboembolism or hematologic abnormalities. Other therapies under clinical evaluation for the treatment of psoriasis are the retinoic acid-related nuclear receptor RORγt inhibitor, which is a master regulator of Th17 cells.

IL-23 inhibitors

IL-23 is believed to be a key regulatory cytokine in the pathogenesis of PsA, and targeting it appears to bring about many of the expected therapeutic effects. Guselkumab, tildrakizumab and risankizumab are three IL-23 inhibitors approved by the European Medicines Agency (EMA) and the Food and Drug Administration (FDA) for the treatment of moderate to severe plaque psoriasis in adult patients (Table 3). By binding to the p19 subunit, guselkumab blocks the binding of extracellular IL-23 to the IL-23 cell surface receptor, thereby inhibiting

<table>
<thead>
<tr>
<th>JAK inhibitors</th>
<th>TYK2 inhibitors</th>
<th>IL-17 inhibitors</th>
<th>IL-23 inhibitors</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tofacitinib (JAK1/3)</td>
<td>Deucravacitinib</td>
<td>Bimekizumab (IL-17A/F)</td>
<td>Guselkumab</td>
</tr>
<tr>
<td>Upadacitinib (JAK1)</td>
<td></td>
<td>Brodalumab (IL-17A/F)</td>
<td>Tildrakizumab</td>
</tr>
<tr>
<td>Filgotinib (JAK1)</td>
<td></td>
<td></td>
<td>Risankizumab</td>
</tr>
</tbody>
</table>

JAK: Janus Kinase; TYK: tyrosine kinase; IL: interleukin.
Table 3. Overview of latest approved IL-23 inhibitors for the treatment of psoriasis.

<table>
<thead>
<tr>
<th>Drug</th>
<th>Structure</th>
<th>Mechanism of action</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>Guselkumab</td>
<td>Human IgG1λ monoclonal antibody</td>
<td>p19 subunit of IL-23</td>
<td>100mg subcutaneous every 8 weeks, post induction</td>
</tr>
<tr>
<td>Tildrakizumab</td>
<td>Humanised IgG1κ monoclonal antibody</td>
<td>p19 subunit of IL-23</td>
<td>100mg subcutaneous every 12 weeks, post induction</td>
</tr>
<tr>
<td>Risankizumab</td>
<td>Humanised IgG1κ monoclonal antibody</td>
<td>p19 subunit of IL-23</td>
<td>150mg subcutaneous every 12 weeks, post induction</td>
</tr>
</tbody>
</table>

IL: interleukin.

IL-23-mediated intracellular signalling, activation, and cytokine production. In a phase 3 study (DISCOVER-1), patients received guselkumab every 4 or every 8 weeks.\(^{37}\) Response rates by ACR20 at week 24 were significantly higher for guselkumab every 4 or every 8 weeks than in placebo (59.4% and 52.0% versus 22.2%, respectively). In DISCOVER-2, a larger study in biologic-naïve patients, guselkumab was administered every 4 or every 8 weeks versus placebo.\(^{38}\) ACR20 response at week 24 was 63.7% and 64.1% versus 32.9%, respectively. The response was clearly greater than in DISCOVER-1, which also included patients with failure of even two TNFα inhibitors. The difference between drug and placebo was also significant in secondary endpoints including radiological progression, enthesitis, and dactylitis. The observed safety profile was similar to previous studies in patients with psoriasis. A meta-analysis comparing guselkumab with targeted therapies in PsA regarding safety and efficacy in joint and skin lesions showed that guselkumab had a very good efficacy in arthritis, (comparable to IL-17A inhibitors and TNFα inhibitors), while providing a better PASI response than many other treatments.\(^{39}\)

Tildrakizumab, also approved for the treatment of moderate to severe plaque psoriasis, is under investigation for the treatment of PsA. In a 2b phase study at week 24, ACR20 response was observed in 71.4-79.5% of tildrakizumab patients versus 50.6% of placebo patients.\(^{40}\) At the same time, phase 3 studies are being conducted to evaluate its effectiveness in PsA. Finally, risankizumab (150mg) also an approved monoclonal antibody against interleukin-23p19 was evaluated in PsA.\(^{41}\) ACR20 response for risankizumab was 57% and 51% vs 34% and 27% for placebo at week 24 with the known safety profile of risankizumab observed in psoriasis. A meta-analysis of clinical trials comparing the safety and benefit-risk profile of biologic and oral therapies in patients with moderate to severe plaque psoriasis showed that anti-IL-23 agents were associated with low rates of adverse events, and that risankizumab had the most favourable long-term benefit-risk profile.\(^{32}\) Of note that, IL-23 inhibitors have not shown a good response to axial disease.

**IL-17 Inhibitors**

Secukinumab, an IL-17A inhibitor, vs adalimumab, a TNFα inhibitor with recognised efficacy and safety in psoriasis, was compared in EXCEED study (a double-blind, randomised, phase 3b trial) in patients with active PsA. In this study secukinumab did not demonstrate superiority (no statistical significance in the primary endpoint of ACR20 response at week 52), but showed higher treatment retention than adalimumab. The conclusions of such comparative studies of two biological agents with different mechanisms of action, could help in making clinical decisions in the management of PsA.\(^{43}\)

Ixekizumab, another IL-17A inhibitor, in a 24-week phase 3 trial (SPIRIT-P2) in patients with active PsA who had failed after treatment of TNFα inhibitors showed that both the 2-week and 4-week regimens improved signs and symptoms in active PsA, ACR20 with ixekizumab every 4 weeks [65 (53%) patients, effect size vs placebo 33.8% (95% CI 22.4-45.2), p<0.0001] and ixekizumab every 2 weeks [59 (48%) patients, 28.5% (17.1-39.8), p=0.0001] versus placebo patients [23 (20%) patients] with a safety profile consistent with previous studies.\(^{44}\) IL-17 inhibitors have shown also a good clinical response to axial disease as well as the IL-17A-F inhibitors.

**IL-17A-F inhibitors**

IL-17A and IL-17F appear to act synergistically in pathological bone formation, thus
suggesting that neutralisation of both cytokines inhibits this process in a better manner than inhibition of IL-17A alone. Bimekizumab in a phase 2b study (BEACTIVE) with 206 patients showed a good efficacy and safety profile in two dosage regimens of 16mg and 160mg (with or without a loading dose of 320mg). The onset of action was rapid with ACR50 response maintained at 48 weeks, and results extended to 152 weeks. Brodalumab, a human IgG2 monoclonal antibody binds with high affinity to the IL-17 receptor (R) and inhibits IL-17A, IL-17E and IL-17F. The AMVISION-1 and AMVISION-2, two randomised phase III trials compared brodalumab with placebo (brodalumab 140mg or 210mg at weeks 0, 1, and every 2 weeks to 24 weeks) in 962 patients. The ACR20 response rates at week 16 in both brodalumab treatment groups were 45.8% and 47.9% for 140mg and 210mg respectively versus placebo 20.9% (p<0.0001). Similar results were seen at week 24. Significantly higher percentages of brodalumab-treated patients also achieved secondary endpoints ACR50/70. Finally, brodalumab was well tolerated with a safety profile consistent with the other IL-17 inhibitors.

FUTURE TREATMENT INSIGHTS

Although the therapeutic armamentarium for the treatment of psoriasis and PsA has expanded significantly over the past thirty years, additional drugs are needed for optimal disease care. Based on efficacy and safety, biologics targeting the IL-23 and IL-17 pathways represent one of the greatest achievements of dermatology in the past decade. In many patients, there may be little or no relationship between the severity of musculoskeletal inflammation and the severity of skin or nail psoriasis. The reason for the heterogeneity of this disease can be explained by differences in different genotypes, especially in the HLA region. New targeted therapies for PsA have been approved and additional therapies are under development. These advances have significantly improved both short- and long-term outcomes, including improvement in musculoskeletal and skin manifestations as well as the reduction of radiographic damage. In the coming years, it needs to be determined which of the modern treatments, including the well-established TNFα therapy, most effectively reduces and/or reverses the comorbidities of psoriatic disease, with an emphasis on metabolic and cardiovascular ones. There is reasonable hope that early use of specific therapies not only eliminates short-lived pathogenic cells but also prevents the emergence and expansion of long-lived pathogenic cells. It is also possible that the patients being just a “cohort number”, may not be considered equally in all studies as far as it concerns sample time, patient age, disease duration and disease severity. This is probably the reason why drugs with the same and/or similar mechanism of action lead to ambiguous results. It also highlights the challenges facing researchers seeking to characterise the pathogenesis of complex autoimmune diseases.

A systematic review and meta-analysis compared treatments for the effectiveness of arthritis (ARC response), psoriasis (PASI), enthesitis, and dactylitis. It also assessed the safety of the drugs on the basis of discontinuation due to adverse effects. It included a total of 46 studies. The results showed that some TNFα inhibitors performed numerically, but without statistical significance, better results than IL-inhibitors in ACR response, but had a worse PASI response. Gusekumab and the IL-17A or IL-17R inhibitors (brodalumab, ixekizumab, secukinumab) were the best in PASI response. IL-inhibitors and adalimumab were equally effective in resolving enthesitis and dactylitis. Infliximab with or without methotrexate, certolizumab 400mg every 4 weeks and tildrakizumab had the highest rates of adverse events. The conclusion was that IL-17A & IL-17R inhibitors and guselkumab offered better efficacy than TNFα inhibitors in the cutaneous manifestations, enthesitis and dactylitis and similar efficacy in ACR response.

CONCLUSIONS

During the last decades, significant advances have been made in the understanding and treatment of psoriatic disease (psoriasis and PsA). However, there is currently no method for predicting the optimal therapeutic strategy, both for well-established and emerging therapies. The choice of drug for the treatment of psoriatic disease should be based on the predominant clinical phenotype, and treatment should be initiated very close to the point of onset of inflammation.

CONFLICT OF INTEREST

The authors declare no conflict of interest.

AUTHOR CONTRIBUTION

Eleftherios Pelechas, Evripidis Kaltsonoudis, Alexandros A Drosos: conception and design of the work.
Evripidis Kaltsonoudis: drafting.
Michalis P Migkos, Nikolaos Koletos, Panagioti G Karagianni: acquisition, analysis of data.
Alexandros A Drosos, Paraskevi V Voulgari: reviewing data and text.

REFERENCES


45. Coates LC, McInnes IB, Merola JF, Warren RB, Kavanaugh A, Gottlieb AB, et al. Safety and Efficacy of Bimekizumab in Patients with Active Psoriatic Arthritis: 3-Year Results from a Phase 2b Randomized Controlled Trial and its Open-Label Extension Study. Arthritis Rheumatol (Hoboken, NJ) 2022;